SRPT

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2007, for AVI BioPharma, Inc. (Note: The input metadata referenced Sarepta Therapeutics, but the filing text explicitly identifies the registrant as AVI BioPharma, Inc.). The company is a development-stage biopharmaceutical firm focused on antisense therapeutics. It has incurred cumulative losses of approximately $222 million since its inception in 1980 and has not generated material revenue from product sales.

Key Financial Metrics

Cash Flow (Six Months Ended June 30, 2007): Net cash used in operating activities was $12,730,038. Net cash provided by investing activities was $1,770,765. Net cash provided by financing activities was $63,584.

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased significantly to $2.35 million for the quarter (from $18,558 in Q2 2006) and $2.89 million for the six months (from $84,520 in the prior year period). This was driven primarily by research contract revenues ($2.31 million increase in Q2) and license fees.
• Expense Increases: Operating expenses rose to $11.19 million for the quarter (from $7.44 million in Q2 2006). Research and Development (R&D) expenses increased by approximately $3.24 million, largely due to expanded clinical programs ($1.4 million) and government contract expensing ($1.75 million).
• Liquidity Decline: Cash and cash equivalents decreased from $20.16 million at year-end 2006 to $9.26 million at June 30, 2007. Total liquid assets (cash + short-term securities) dropped from $33.15 million to $19.32 million.
• Debt Assumption: The company assumed long-term debt of approximately $2.2 million in connection with a real estate purchase in April 2007.

Guidance, Outlook, and Risks

• Outlook: Management expects to incur operating losses for the foreseeable future. For 2007, the company expects expenditures for operations (net of government funding) to be approximately $24 million to $26 million.
• Liquidity Position: The company believes it has sufficient cash to fund operations through 2007. However, it will require substantial additional financing to continue operations beyond 2007. Failure to secure capital may force curtailment of clinical programs and R&D.
• Key Contracts:
  • DTRA Contract: A two-year, $28 million contract with the Defense Threat Reduction Agency for antisense therapeutics against hemorrhagic viruses. Approximately $18 million is committed for the first year.
  • Defense Appropriations: An allocation of $11.0 million (net ~$9.8 million) for defense-related programs, with signed contracts totaling $7.1 million.
• Management Changes: The former Chairman and CEO resigned in March 2007. K. Michael Forrest was appointed Interim CEO. The company is searching for a permanent replacement, which poses a risk to R&D efforts if not secured successfully.
• Risk Factors: The company is a development-stage entity with no product sales. Success depends on completing product development, obtaining regulatory approvals, and securing future financing. There is no assurance of profitability.

Investor Verification Checklist

• Verify the sufficiency of the $19.3 million in liquid assets to cover the projected $24–$26 million operating burn rate for the remainder of 2007.
• Confirm the status of the search for a permanent CEO and the potential impact of leadership transition on clinical trial timelines.
• Review the terms and funding schedules of the $28 million DTRA contract and the $11 million defense appropriation to ensure expected cash inflows align with operational needs.
• Assess the impact of the $2.2 million debt assumption for the new facility on future cash flow and interest obligations.
• Monitor the progress of clinical programs, as delays could necessitate further capital raises or expenditure curtailments.